[go: up one dir, main page]

WO2008120725A1 - 新規ピロリノン誘導体およびそれを含有する医薬組成物 - Google Patents

新規ピロリノン誘導体およびそれを含有する医薬組成物 Download PDF

Info

Publication number
WO2008120725A1
WO2008120725A1 PCT/JP2008/056107 JP2008056107W WO2008120725A1 WO 2008120725 A1 WO2008120725 A1 WO 2008120725A1 JP 2008056107 W JP2008056107 W JP 2008056107W WO 2008120725 A1 WO2008120725 A1 WO 2008120725A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
composition containing
medicinal composition
novel
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2008/056107
Other languages
English (en)
French (fr)
Inventor
Hiroyuki Kai
Shunji Shinohara
Takayuki Kameyama
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Priority to US12/450,548 priority Critical patent/US8101644B2/en
Priority to EP08739225A priority patent/EP2143713A4/en
Priority to JP2009507522A priority patent/JP5624762B2/ja
Priority to CA002682473A priority patent/CA2682473A1/en
Priority to CN200880017760A priority patent/CN101679246A/zh
Publication of WO2008120725A1 publication Critical patent/WO2008120725A1/ja
Anticipated expiration legal-status Critical
Priority to US13/242,518 priority patent/US8497263B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/38—2-Pyrrolones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

　本発明は、Ｐ２Ｘ3および／またはＰ２Ｘ2/3アンタゴニストとして有用な、式（Ｉ）： ［式中、Ｒ1、Ｒ2、Ｒ3、Ｚ1、Ｚ2、Ｒa、Ｒb、ｑ、Ａおよびｎは、明細書において定義するとおりである］で表される化合物、製薬上許容される塩またはそれらの溶媒和物を提供する。
PCT/JP2008/056107 2007-03-30 2008-03-28 新規ピロリノン誘導体およびそれを含有する医薬組成物 Ceased WO2008120725A1 (ja)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US12/450,548 US8101644B2 (en) 2007-03-30 2008-03-28 Pyrrolinone derivative and pharmaceutical composition comprising the same
EP08739225A EP2143713A4 (en) 2007-03-30 2008-03-28 NEW PYRROLINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING THIS
JP2009507522A JP5624762B2 (ja) 2007-03-30 2008-03-28 新規ピロリノン誘導体およびそれを含有する医薬組成物
CA002682473A CA2682473A1 (en) 2007-03-30 2008-03-28 Novel pyrrolinone derivative and pharmaceutical composition comprising the same
CN200880017760A CN101679246A (zh) 2007-03-30 2008-03-28 新型吡咯啉酮衍生物以及包含其的药物组合物
US13/242,518 US8497263B2 (en) 2007-03-30 2011-09-23 Pyrrolinone derivative and pharmaceutical composition comprising the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007091624 2007-03-30
JP2007-091624 2007-03-30

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/450,548 A-371-Of-International US8101644B2 (en) 2007-03-30 2008-03-28 Pyrrolinone derivative and pharmaceutical composition comprising the same
US13/242,518 Division US8497263B2 (en) 2007-03-30 2011-09-23 Pyrrolinone derivative and pharmaceutical composition comprising the same

Publications (1)

Publication Number Publication Date
WO2008120725A1 true WO2008120725A1 (ja) 2008-10-09

Family

ID=39808305

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/056107 Ceased WO2008120725A1 (ja) 2007-03-30 2008-03-28 新規ピロリノン誘導体およびそれを含有する医薬組成物

Country Status (8)

Country Link
US (2) US8101644B2 (ja)
EP (1) EP2143713A4 (ja)
JP (1) JP5624762B2 (ja)
KR (1) KR20100016076A (ja)
CN (1) CN101679246A (ja)
CA (1) CA2682473A1 (ja)
TW (1) TW200843739A (ja)
WO (1) WO2008120725A1 (ja)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010035727A1 (ja) * 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2011004017A1 (en) * 2009-07-10 2011-01-13 Vivalis 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
WO2011004018A1 (en) * 2009-07-10 2011-01-13 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
JP2011518133A (ja) * 2008-04-09 2011-06-23 サントル・ナショナル・ドゥ・ラ・レシェルシュ・サイエンティフィーク−セ・エン・エール・エス− Ｓｙｋチロシンキナーゼタンパク質が関与している代謝経路を阻害する分子および前記分子を同定するための方法
JP2013237688A (ja) * 2006-11-09 2013-11-28 Probiodrug Ag 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
JP2014533745A (ja) * 2011-11-29 2014-12-15 ノバルティス アーゲー ピラゾロピロリジン化合物
WO2015004610A1 (en) 2013-07-11 2015-01-15 Adamed Sp. Z O.O. 1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
US9051279B2 (en) 2009-12-22 2015-06-09 Novartis Ag Substituted isoquinolinones and quinazolinones
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
JP2016520118A (ja) * 2013-05-28 2016-07-11 ノバルティス アーゲー Ｂｅｔ阻害剤としてのピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
US9890166B2 (en) 2013-05-27 2018-02-13 Novartis Ag Imidazopyrrolidine derivatives and their use in the treatment of disease
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
CN117157296A (zh) * 2021-01-21 2023-12-01 首都医科大学附属北京天坛医院 Fpr1的调节剂及其使用方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2682473A1 (en) * 2007-03-30 2008-10-09 Shionogi & Co., Ltd. Novel pyrrolinone derivative and pharmaceutical composition comprising the same
US9212130B2 (en) * 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
GB201016880D0 (en) * 2010-10-07 2010-11-17 Riotech Pharmaceuticals Ltd Phosphodiesterase inhibitors
US9550763B2 (en) * 2012-02-09 2017-01-24 Shionogi & Co., Ltd. Heterocyclic ring and carbocyclic derivative
CN103819476B (zh) * 2013-03-05 2016-08-17 中国人民解放军第二军医大学 吡咯酮并吡唑类化合物及其作为药物的用途
CN104447733B (zh) * 2015-01-05 2016-08-17 中国药科大学 1-苄基-2-吡咯啉酮-4-酰胺类化合物及其制备方法与应用
CN112142742B (zh) * 2019-06-26 2022-01-07 香港理工大学深圳研究院 Ctcf转录因子抑制剂及其应用
CN111138289B (zh) * 2020-02-27 2022-08-30 奥锐特药业(天津)有限公司 一种化合物及使用该化合物合成5-乙酰基-1h-吡唑-3-羧酸的工艺

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094767A2 (en) 2001-05-18 2002-11-28 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
WO2005095359A1 (en) 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
WO2006044000A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Sulfonamide pert-substituted bicyclics for occlusive artery disease
US20070037974A1 (en) 2005-08-15 2007-02-15 Roche Palo Alto Llc Inhibitors of P2X3
US20070049609A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
US20070049534A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators
US20070049758A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators
US20070049610A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2097038A1 (en) 1970-07-29 1972-03-03 Bellon Labor Sa Roger 1-(substd phenyl)-2-oxo-4-piperazinocarbonyl pyrrolidines - analgesic
US5508300A (en) * 1994-01-14 1996-04-16 Pfizer Inc. Dihydro pyrazolopyrroles, compositions and use
RU2067575C1 (ru) 1994-07-27 1996-10-10 Пермский фармацевтический институт 4-ацетил-5-п-иодфенил-1-карбоксиметил-3-гидрокси-2,5-дигидропиррол-2-он, проявляющий анальгетическую активность
RU2004109818A (ru) * 2001-10-03 2005-05-10 Юсиби, С.А. (Be) Производные пирролидинона
DE102006025318A1 (de) * 2006-05-31 2007-12-06 Bayer Healthcare Ag Dihydro-pyrrolopyridin-, Dihydro-pyrrolopyridazin- und Dihydro-pyrrolopyrimidin-Derivate und ihre Verwendung
CA2682473A1 (en) * 2007-03-30 2008-10-09 Shionogi & Co., Ltd. Novel pyrrolinone derivative and pharmaceutical composition comprising the same
TW201016702A (en) * 2008-09-25 2010-05-01 Shionogi & Co Novel pyrrolinone derivative and pharmaceutical composition comprising the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002094767A2 (en) 2001-05-18 2002-11-28 Abbott Laboratories Trisubstituted-n-[(1s)-1,2,3,4-tetrahydro-1-naphthalenyl] benzamides which inhibit p2x3 and p2x2/3 containing receptors
WO2005095359A1 (en) 2004-03-05 2005-10-13 F. Hoffmann-La Roche Ag Diaminopyrimidines as p2x3 and p2x2/3 antagonists
WO2006044000A1 (en) * 2004-10-12 2006-04-27 Decode Genetics Sulfonamide pert-substituted bicyclics for occlusive artery disease
US20070037974A1 (en) 2005-08-15 2007-02-15 Roche Palo Alto Llc Inhibitors of P2X3
US20070049609A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Methods of using diaminopyrimidine P2X3 and P2X2/3 receptor modulators for treatment of respiratory and gastrointestinal diseases
US20070049534A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators
US20070049758A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators
US20070049610A1 (en) 2005-09-01 2007-03-01 Roche Palo Alto Llc Diaminopyrimidines as P2X3 and P2X2/3 modulators

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
DATABASE REGISTRY [online] 6 April 2004 (2004-04-06), XP008114737, accession no. STN Database accession no. (671764-08-2) *
EXPERT OPIN. THER. PATENS, vol. 16, no. 8, 2006, pages 113 - 1127
GEIN V.L. ET AL.: "Synthesis and antiinflammatory and analgesic activity of 1-(2-aminoethyl)-5-aryl-4-acyl-3-hydroxy-3-pyrrolin-2-ones", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 39, no. 9, 2005, pages 484 - 487, XP019223697 *
GEIN V.L. ET AL.: "Synthesis and biological activity of 5-aryl-4-acyl-3-hydroxy-1-morpholinoalkyl-3-pyrrolin-2-ones", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 41, no. 5, 18 November 2007 (2007-11-18), pages 256 - 263, XP019555868 *
GEIN V.L. ET AL.: "Synthesis and pharmacological activity of 5-aryl-4-acetyl-1-carboxylalkyltetrahydropyrrole-2,3-diones", KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 31, no. 5, 1997, pages 33 - 36, XP008136051 *
J. PHYSIOL., vol. 567.2, 2005, pages 621 - 639
J. PHYSIOLOGY, vol. 553, no. 3, 2003, pages 683 - 694
J. PHYSIOLOGY, vol. 554, no. 2, 2003, pages 301 - 308
KOZ'MINYCH E.N. ET AL.: "1,3,4,6-Tetracarbonyl compounds. Part 2. Preparation of biologically active 2-hydroxy-2,3-diyhdro-3-pyrrolones and aroylpyruvic acid-substituted amides", KHIMIKO-FARMATSEVTICHESKII ZHURNAL, vol. 30, no. 7, 1996, pages 31 - 35, XP008136318 *
NATURE, vol. 407, no. 26, 2000, pages 1011 - 1015
NATURE, vol. 407, no. 26, 2000, pages 1015 - 1017
NEUROSCIENTIST, vol. 11, 2005, pages 345 - 356
PFLUNGERS ARCH EUR J PHYSIOL, vol. 452, 2006, pages 513 - 537
PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 31, no. 5, 1997, pages 251 - 254
PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 39, no. 9, 2005, pages 484 - 487
PNAS, vol. 99, no. 26, 2002, pages 17179 - 17184
See also references of EP2143713A4
ZANKOWSKA-JASINSKA W. ET AL.: "the new synthesis of the pyrrolo[3,4-e][1,4]diazepine derivatives", ZESZYTY NAUKOWE UNIWERSYTETU JAGIELLONSKIEGO, PRACE CHEMICZNE, vol. 32, 1989, pages 75 - 82, XP008136400 *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013237688A (ja) * 2006-11-09 2013-11-28 Probiodrug Ag 潰瘍、癌及び他の疾患の治療のためのグルタミニルシクラーゼの阻害薬としての３−ヒドロキシ−１，５−ジヒドロ−ピロール−２−オン誘導体
JP2015061837A (ja) * 2008-04-09 2015-04-02 サントル・ナショナル・ドゥ・ラ・レシェルシュ・サイエンティフィーク−セ・エン・エール・エス− Ｓｙｋチロシンキナーゼタンパク質が関与している代謝経路を阻害する分子および前記分子を同定するための方法
JP2011518133A (ja) * 2008-04-09 2011-06-23 サントル・ナショナル・ドゥ・ラ・レシェルシュ・サイエンティフィーク−セ・エン・エール・エス− Ｓｙｋチロシンキナーゼタンパク質が関与している代謝経路を阻害する分子および前記分子を同定するための方法
EP2336109A4 (en) * 2008-09-25 2012-05-02 Shionogi & Co NOVEL PYRROLINONE DERIVATIVE AND DRUG COMPOSITION CONTAINING THE SAME
US8575197B2 (en) 2008-09-25 2013-11-05 Shionogi & Co., Ltd. Pyrolinone derivative and pharmaceutical composition comprising the same
WO2010035727A1 (ja) * 2008-09-25 2010-04-01 塩野義製薬株式会社 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2011004017A1 (en) * 2009-07-10 2011-01-13 Vivalis 1-(6 members azo-heterocyclic)-pyrrolin-2-one compounds as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
WO2011004018A1 (en) * 2009-07-10 2011-01-13 Vivalis Substituted pyrrolidinone as inhibitors of hepatitis c ns5b polymerase, the pharmaceutical composition thereof and their therapeutic use
US9051279B2 (en) 2009-12-22 2015-06-09 Novartis Ag Substituted isoquinolinones and quinazolinones
JP2014533745A (ja) * 2011-11-29 2014-12-15 ノバルティス アーゲー ピラゾロピロリジン化合物
US8969341B2 (en) 2011-11-29 2015-03-03 Novartis Ag Pyrazolopyrrolidine compounds
US8815926B2 (en) 2012-01-26 2014-08-26 Novartis Ag Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
US9365576B2 (en) 2012-05-24 2016-06-14 Novartis Ag Pyrrolopyrrolidinone compounds
US9737522B2 (en) 2012-08-09 2017-08-22 Emory University NMDA receptor modulators and uses related thereto
US9556180B2 (en) 2013-01-22 2017-01-31 Novartis Ag Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
US9403827B2 (en) 2013-01-22 2016-08-02 Novartis Ag Substituted purinone compounds
US9890166B2 (en) 2013-05-27 2018-02-13 Novartis Ag Imidazopyrrolidine derivatives and their use in the treatment of disease
JP2016520117A (ja) * 2013-05-27 2016-07-11 ノバルティス アーゲー ピラゾロピロリジン誘導体および疾患の処置におけるその使用
US8975417B2 (en) 2013-05-27 2015-03-10 Novartis Ag Pyrazolopyrrolidine derivatives and their use in the treatment of disease
US9714249B2 (en) 2013-05-28 2017-07-25 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives and their use in the treatment of disease
US9624247B2 (en) 2013-05-28 2017-04-18 Novartis Ag Pyrazolo-pyrrolidin-4-one derivatives as bet inhibitors and their use in the treatment of disease
JP2016520118A (ja) * 2013-05-28 2016-07-11 ノバルティス アーゲー Ｂｅｔ阻害剤としてのピラゾロ−ピロリジン−４−オン誘導体および疾患の処置におけるその使用
WO2015004610A1 (en) 2013-07-11 2015-01-15 Adamed Sp. Z O.O. 1,5-dihydropyrrol-2-one derivatives as inhibitors of p53-mdm2/mdm4 protein-protein interaction
US9550796B2 (en) 2013-11-21 2017-01-24 Novartis Ag Pyrrolopyrrolone derivatives and their use as BET inhibitors
WO2020179859A1 (ja) 2019-03-06 2020-09-10 第一三共株式会社 ピロロピラゾール誘導体
KR20210135521A (ko) 2019-03-06 2021-11-15 다이이찌 산쿄 가부시키가이샤 피롤로피라졸 유도체
US12240855B2 (en) 2019-03-06 2025-03-04 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
CN117157296A (zh) * 2021-01-21 2023-12-01 首都医科大学附属北京天坛医院 Fpr1的调节剂及其使用方法
EP4281452A4 (en) * 2021-01-21 2024-11-06 Beijing Tiantan Hospital MODULATORS OF FPR1 AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
JP5624762B2 (ja) 2014-11-12
US20100210632A1 (en) 2010-08-19
CA2682473A1 (en) 2008-10-09
US20120010199A1 (en) 2012-01-12
KR20100016076A (ko) 2010-02-12
TW200843739A (en) 2008-11-16
EP2143713A1 (en) 2010-01-13
US8101644B2 (en) 2012-01-24
US8497263B2 (en) 2013-07-30
CN101679246A (zh) 2010-03-24
JPWO2008120725A1 (ja) 2010-07-15
EP2143713A4 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2007048064A3 (en) Amino-pyrimidines as casein kinase ii (ck2) modulators
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MY147211A (en) Novel dihydropseudoerythromycin derivatives
WO2009016560A3 (en) Trans-3-aza-bicyclo[3.1.0]hexane derivatives
MY186650A (en) Heteroaryl pyrrolidinyl and piperidinyl ketone derivatives
WO2008044243A3 (en) Novel process for the preparation of statins and their pharmaceutically acceptable salts thereof
WO2006072393A3 (de) Sulfonylpyrrolidine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
WO2006010546A3 (en) Aryl-pyridine derivatives as 11-beta-hsd1 inhibitors
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2007147771A3 (en) Tetralin and indane derivatives and uses thereof
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
UA96759C2 (en) 2-ARYLINDOLE DERIVATIVES AS mPGES-I INHIBITORS
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
WO2006077025A3 (en) Morpholines as 5ht2c agonists
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
WO2008116185A3 (en) Substituted pyrimidines as adenosine receptor antagonists
WO2008104473A3 (en) Pyrazolopyriidine derivatives and their use as kinase inhibitors
WO2007075964A8 (en) Thrombin receptor antagonists as prophylaxis to complications from cardiopulmonary surgery
MY144050A (en) Tetralin and indane derivatives and uses thereof
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880017760.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08739225

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009507522

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2682473

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 12450548

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008739225

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097022735

Country of ref document: KR

Kind code of ref document: A